What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...
Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone dysregulation, often driven by obesity and primary aldosteronism, affects ...
Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and ...
There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), ...
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a ...
A clinical trial has seen promising results from a new class of medication to treat hypertension. Design by MNT; Photography by Peca King/500px/Getty Images & MementoJpeg/Getty Images Blood pressure ...
A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results